Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928502 | 0.85 | RORC (0.37) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL6330682 | 0.84 | GPR119 (0.41) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL6324664 | 0.83 | HPGDS (0.53) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL930420 | 0.81 | USP30 (0.43) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL927931 | 0.81 | USP30 (0.58) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL929141 | 0.80 | SCD5 (0.48) | USP30HPGDSHDAC8HDAC6 | |
| SCHEMBL6324403 | 0.79 | USP30 (0.44) | USP30HPGDSCKS1BSKP1SKP2 | |
| SCHEMBL928428 | 0.78 | USP30 (0.42) | USP30HPGDSGPR119TAOK3 | |
| SCHEMBL3580207 | 0.77 | GPR119 (0.50) | USP30HPGDSGPR119 | |
| SCHEMBL928369 | 0.77 | USP30 (0.41) | USP30HPGDSGPR119TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | USP30 4503/4885HPGDS 3755/4885CKS1B 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.